Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Syntacoll receives European patents for wound care products
The first patent is for an advanced wound care product comprised of a collagen or other natural polymer layer adhered to a synthetic polymer foam in a non-occlusive,
The first patent is for an advanced wound care product comprised of a collagen or other natural polymer layer adhered to a synthetic polymer foam in a non-occlusive,
The trial will compare two concentrations of epinastine (0.1% and 0.15%) at two different spray volumes to placebo in approximately 750 subjects who have a documented history of
The primary objective of the Phase I/II study is to determine the safety and maximum tolerated dose of GRN163L when administered intravenously in patients with multiple myeloma who
This enrollment was completed ahead of schedule. The results from the trial are expected to be available in the second half of 2008. The company said that this
The trial was designed to determine absorption of Nestorone and estradiol using the Advanced Transdermal Delivery (ATD) gel system. A total of 12 postmenopausal women were selected for
Immunosyn holds the exclusive license for worldwide marketing rights of the drug, SF-1019, while Biozyme Laboratories has agreed to manufacture SF-1019. The license approvals currently granted by the
The European marketing authorization of Cyanokit is supported by safety data in healthy adults and efficacy data in adults and pediatrics, including data from three studies carried out
The current study is intended to expand the clinical data on the accelerated fusion rates as well as show a decrease in non-unions versus traditional plates and screws.
RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal
The study includes chronic lymphocytic leukemia (CLL) patients who are refractory to both fludarabine and alemtuzumab and patients who are refractory to fludarabine and who are considered inappropriate